More great news to share from Clinipace – we just closed a $9 million series C2 round of funding.  This announcement comes on the heels of our September merger with Paragon Biomedical.

This latest round of funding, which includes both new and existing investors, is part of a growth fund and will support ongoing operations as well as Clinipace’s growth strategy. This means hiring additional staff to support new clients and projects.

Within the past three years, Clinipace has created a strong global footprint along with a powerful mix of therapeutic expertise, clinical operations, and regulatory and strategic development services.

As we look ahead, our goal remains be the leader in deploying technology-amplified dCRO services to emerging, venture-backed, mid-tier and strategic biopharmaceutical and medical device firms, while conducting clients’ regulatory and clinical development programs to the highest levels of quality and efficiency and helping them bring new medical therapies to market.